2007年毕业于浙江大学药学院，获得学士学位。同年于协和医学院医药生物技术研究所攻读博士学位，2012年毕业后一直任职于药物研究所。主要从事抗肿瘤药物的机制研究和小分子抗肿瘤药物的研发，包括IDO, PD-1/PD-L1，KRAS，CDK8和PI3K/HADC等等。发表SCI一作文章10余篇；参与申请国内外专利20余项，获得授权专利8项。主持和参与多项科研项目，包括：国家自然科学基金青年项目、药物所基本科研业务费、十三五创新药物重大科技专项、创新工程重大协同创新项目和国家自然科学基金面上项目等。

肿瘤药理，肿瘤免疫，抗肿瘤药物研发

[1] C. Zhou1, F. Lai1, Sheng, X. Chen, Y. Li, Z. Feng, Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors, Molecules, 25 (2020).
[2] Y. Zang1, F. Lai1, J. Fu, C. Li, J. Ma, C. Chen, K. Liu, T. Zhang, X. Chen, D. Zhang, Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies, Eur J Med Chem, 190 (2020) 112079.
[3] G. Cui1, F. Lai1, X. Wang, X. Chen, B. Xu, Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors, Eur J Med Chem, 188 (2020) 111985.
[4] K. Zhang1, F. Lai1, S. Lin, M. Ji, J. Zhang, Y. Zhang, J. Jin, R. Fu, D. Wu, H. Tian, N. Xue, L. Sheng, X. Zou, Y. Li, X. Chen, H. Xu, Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases, J Med Chem, 62 (2019) 6992-7014.
[5] N. Xue1, F. Lai1, T. Du, M. Ji, D. Liu, C. Yan, S. Zhang, X. Yu, J. Jin, X. Chen, Chaperone-mediated autophagy degradation of IGF-1Rbeta induced by NVP-AUY922 in pancreatic cancer, Cell Mol Life Sci, 76 (2019) 3433-3447.
[6] J. Jin1, M. Ji, R. Fu, M. Wang, N. Xue, Q. Xiao, J. Hu, X. Wang, F. Lai*, D. Yin*, X. Chen*, Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis, Front Pharmacol, 10 (2019) 1085.
[7] Q. Zhang1, S. Xu1, F. Lai1, Y. Wang, N. Zhang, M. Nazare, H.Y. Hu, Rapid Synthesis of gamma-Halide/Pseudohalide-Substituted Cyanine Sensors with Programmed Generation of Singlet Oxygen, Org Lett, 21 (2019) 2121-2125.
[8] Y. He1, J. Wen, Q. Cui, F. Lai*, D. Yin*, H. Cui*, Quantitative Evaluation of in Vivo Target Efficacy of Anti-tumor Agents via an Immunofluorescence and EdU Labeling Strategy, Front Pharmacol, 9 (2018) 812.
[9] F. Lai1, Z. Shen1, H. Wen, J. Chen, X. Zhang, P. Lin, D. Yin, H. Cui, X. Chen, A Morphological identification cell cytotoxicity assay using cytoplasm-localized fluorescent probe (CLFP) to distinguish living and dead cells, Biochem Biophys Res Commun, 482 (2017) 257-263.
[10] F. Lai1, Q. Liu1, X. Liu, M. Ji, P. Xie, X. Chen, LXY6090 - a novel manassantin A derivative - limits breast cancer growth through hypoxia-inducible factor-1 inhibition, Onco Targets Ther, 9 (2016) 3829-3840.
[11] F. Lai1, N. Madan, Q1. Ye, Q. Duan, Z. Li, S. Wang, S. Si, Z. Xie, Identification of a mutant alpha1 Na/K-ATPase that pumps but is defective in signal transduction, J Biol Chem, 288 (2013) 13295-13304.
[12] Q. Ye1, F. Lai1, M. Banerjee, Q. Duan, Z. Li, S. Si, Z. Xie, Expression of mutant alpha1 Na/K-ATPase defective in conformational transition attenuates Src-mediated signal transduction, J Biol Chem, 288 (2013) 5803-5814.
[13] Y. Xu1, F. Lai1, Y. Xu, Y. Wu, Q. Liu, N. Li, Y. Wei, T. Feng, Z. Zheng, W. Jiang, L. Yu, B. Hong, S. Si, Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARgamma-LXRalpha-ABCA1 pathway, Biochem Biophys Res Commun, 414 (2011) 779-782.

1.《中国药用植物志》艾铁民主编，中国科学出版社，2016年
2.《中华医学百科全书 肿瘤学（五）》，石远凯、刘德培主编，中国协和医科大学出版社，2020年

1. 苄苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。申请日期：2017.05.23. 授权日期：2021.03.09（美国）。
2. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。申请日期：2017.05.23. 授权日期：2020.11.03（俄罗斯）. 授权日期：2021.04.13（美国）。
3. 溴代苄醚衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,张莉婧,杨阳,来芳芳,季鸣,周川,郑义,薛妮娜,李凌。申请日期：2017.05.23。
4. 苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,周川,来芳芳,季鸣,金小锋,薛妮娜,郑义,陈浩,李凌。申请日期：2017.05.23. 授权日期：2021.01.05（美国）。
5. 苄苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。申请日期：2017.05.23。
6. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。申请日期：2017.05.23。

2020年，“梁周黄于刘青年科技奖”-三等奖，药物所